-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35

Benzinga·06/30/2026 15:34:57
Listen to the news
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $34 to $35.